Respiratory Syncytial Virus (RSV) Fusion Inhibitors Global Market Report 2025
상품코드:1889554
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
호흡기세포융합바이러스(RSV) 융합 억제제 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년의 12억 6,000만 달러에서 2025년에는 14억 8,000만 달러에 달하고, CAGR 17.0%로 성장할 것으로 전망되고 있습니다. 지난 수년간의 성장은 RSV 감염증 증가세, 호흡기 질환에 대한 인식 증가, 노인 인구 증가, 소아 의료시설의 확충, 호흡기 질환으로 의한 입원 환자 증가, 면역 결핍 환자에 대한 주목의 강화 등의 요인에 의해 발생하였습니다.
호흡기세포융합바이러스(RSV) 융합 억제제 시장 규모는 향후 수년간 빠른 성장이 예상됩니다. 2029년에는 27억 3,000만 달러에 달하고, CAGR은 16.6%를 나타낼 전망입니다. 예측기간의 성장은 예방의료에 대한 수요 증가, 호흡기 건강에 관한 정부 시책의 강화, 연구 협력의 확대, 고위험 집단에 대한 중점적 대처, 호흡기 감염증 관리에 대한 인식 향상, 세계의 의료 인프라의 확충에 기인할 전망입니다. 예측 기간의 주요 동향으로는 약물 전달 시스템의 기술적 진보, 단일클론항체 제제의 혁신, 장기간 작용하는 생물학적 제제의 개발, 신규 융합 억제제의 연구 개발, 흡입 및 나잘 스프레이 요법의 진전이 있습니다.
호흡기 감염의 발생률 증가는 향후 수년간 호흡기세포융합바이러스(RSV) 융합 억제제 시장의 성장을 견인할 것으로 예측됩니다. 호흡기 감염은 유해한 미생물이 기도에 침입, 증식함으로써 발생하며 감기, 인플루엔자, 폐렴 등의 질환을 일으킵니다. 이 증가는 주로 대기 오염의 악화로 인한 것이며, 대기 오염은 호흡기 시스템을 약화시키고 감염에 대한 감수성을 높입니다. RSV 융합 억제제는 바이러스의 융합을 특이적으로 억제하고 바이러스가 숙주 세포에 침입하는 것을 방지함으로써 치료 효과를 향상시킵니다. 이러한 억제제는 RSV 감염의 중증도와 지속 기간을 줄이고, 입원률을 낮추며, 환자의 예후를 개선함으로써 호흡기 질환 관리에 대한 목표를 달성하는 효과적인 접근법을 제공합니다. 예를 들어, 2025년 5월 미국 비영리 단체인 뉴욕 과학 아카데미의 보고에 따르면 백일해 증례 수가 8,000건을 돌파하여 2024년 동기의 2배 이상에 달했습니다. 따라서 호흡기 감염의 증가 경향은 RSV 융합 억제제 시장의 성장을 뒷받침하고 있습니다.
의료 지출 증가는 RSV 융합 억제제 시장의 성장을 지원할 것으로 예측됩니다. 의료 지출이란 건강 상태의 유지, 개선을 목적으로 한 의료 서비스, 치료, 시설, 연구, 공중 보건 시책에 소비되는 총 자금을 말합니다. 의료 지출 증가의 배경에는 장기적이고 고액의 치료가 필요한 만성 질환의 증가 추세가 있습니다. 의료 지출의 확대는 연구개발에 대한 자금 제공과 혁신적 치료법의 보급 촉진을 통해 RSV 융합 억제제의 개발을 지원합니다. 또한 의료 제공업체의 도입 확대를 촉진하여 예방, 치료, 환자 예후를 개선할 수 있습니다. 예를 들어, 2024년 5월에 영국 정부 기관인 국가 통계국이 발표한 바에 따르면, 2023년의 총 의료 지출은 전년 대비 5.6% 증가해, 2022년에 비해 0.9%의 성장을 나타냈습니다. 따라서, 의료비 증가가 RSV 융합 억제제 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 성장률 분석
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 실적 : 규모와 성장(2019-2024년)
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
저분자 억제제
단일클론항체
펩티드 억제제
기타 약제
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
경구
정맥내
흡입
기타 투여 경로
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
예방
치료
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원
클리닉
연구기관
기타 최종 사용자
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 세분화 : 저분자 억제제, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
단백질 융합 억제제
바이러스 침입 억제제
복제 억제제
뉴클레오시드 아날로그
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 세분화 : 단일클론항체, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
중화항체
예방용 항체
치료용 항체
복합 항체
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 세분화 : 펩티드 억제제, 유형별, 분석과 예측
융합 억제 펩티드
수용체 결합 펩티드
침입 억제 펩티드
합성 펩티드
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 세분화 : 기타 약제, 유형별, 분석과 예측
리보핵산(RNA) 간섭제
숙주 표적형 억제제
면역조절제
소형 간섭 분자
제7장 지역별 및 국가별 분석
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 경쟁 구도
호흡기세포융합바이러스(RSV) 융합 억제제 시장 : 기업 프로파일
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Gilead Sciences Inc.
Johnson & Johnson
Taisho Pharmaceutical Co. Ltd.
Enanta Pharmaceuticals Inc.
Shanghai Ark Biopharmaceutical Co. Ltd.
Medivir AB
ARNAV Biotech
제32장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
호흡기세포융합바이러스(RSV) 융합 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
호흡기세포융합바이러스(RSV) 융합 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
호흡기세포융합바이러스(RSV) 융합 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Respiratory syncytial virus (RSV) fusion inhibitors are antiviral agents that stop RSV from entering host cells by blocking the fusion of the viral envelope with the cell membrane. These inhibitors act on the viral F-protein, helping reduce infection severity, slow disease progression, and lower hospitalization risk, particularly for infants, older adults, and immunocompromised individuals.
The key drug types of respiratory syncytial virus (RSV) fusion inhibitors include small molecule inhibitors, monoclonal antibodies, peptide inhibitors, and others. Small molecule inhibitors are low-molecular-weight drugs that block RSV infection by targeting the viral fusion protein, preventing viral entry, fusion, or replication in host cells. These are administered through various routes, including oral, intravenous, inhalation, and others, and are used for prophylaxis and treatment, serving end-users such as hospitals, clinics, research institutes, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The respiratory syncytial virus (RSV) fusion inhibitors market research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus (RSV) fusion inhibitors market statistics, including respiratory syncytial virus (RSV) fusion inhibitors industry global market size, regional shares, competitors with a respiratory syncytial virus (RSV) fusion inhibitors market share, detailed respiratory syncytial virus (RSV) fusion inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (RSV) fusion inhibitors industry. This respiratory syncytial virus (RSV) fusion inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The respiratory syncytial virus (RSV) fusion inhibitors market size has grown rapidly in recent years. It will grow from $1.26 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period resulted from the increasing prevalence of RSV infections, growing awareness of respiratory diseases, a rising geriatric population, the expansion of pediatric healthcare facilities, increasing hospital admissions for respiratory illnesses, and a stronger focus on immunocompromised patients.
The respiratory syncytial virus (RSV) fusion inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.73 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period will stem from growing demand for preventive therapies, rising government initiatives for respiratory health, increasing research collaborations, greater emphasis on high-risk populations, rising awareness of respiratory infection management, and the expansion of global healthcare infrastructure. Major trends in the forecast period include technological advancements in drug delivery systems, innovations in monoclonal antibody formulations, developments in long-acting biologics, research and development of novel fusion inhibitors, and advancements in inhalation and nasal spray therapies.
The rising incidence of respiratory infections is expected to drive the growth of the respiratory syncytial virus (RSV) fusion inhibitors market in the coming years. Respiratory infections occur when harmful microorganisms invade and multiply in the respiratory tract, causing illnesses such as colds, flu, or pneumonia. This increase is largely driven by rising air pollution, which weakens the respiratory system and makes individuals more susceptible to infections. RSV fusion inhibitors improve treatment by specifically blocking viral fusion, preventing the virus from entering host cells. These inhibitors reduce the severity and duration of RSV infections, lower hospitalization rates, and enhance patient outcomes, offering a targeted and effective approach to managing respiratory illnesses. For instance, in May 2025, the New York Academy of Sciences, a U.S.-based nonprofit organization, reported that whooping cough cases had surpassed 8,000, more than double the number observed during the same period in 2024. Therefore, the growing prevalence of respiratory infections is propelling the RSV fusion inhibitors market.
Rising healthcare expenditure is expected to support the growth of the RSV fusion inhibitors market. Healthcare expenditure refers to the total funds spent on medical services, treatments, facilities, research, and public health initiatives aimed at maintaining or improving health outcomes. The increase in healthcare spending is driven by the rising prevalence of chronic diseases, which often require long-term and costly treatment. Higher healthcare expenditure supports the development of RSV fusion inhibitors by providing more funding for research, development, and broader accessibility of innovative therapies. It also facilitates wider adoption by healthcare providers, improving prevention, treatment, and patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in total healthcare expenditure in 2023, reflecting a 0.9% growth compared to 2022. Consequently, rising healthcare spending is fueling the growth of the RSV fusion inhibitors market.
Companies in the RSV fusion inhibitors market are increasingly focusing on advanced prophylactic solutions, such as long-acting monoclonal antibodies, to enhance immunity, extend protection, and reduce the burden of infectious diseases in vulnerable populations. Long-acting monoclonal antibodies (mAbs) are engineered to remain active in the body for longer periods compared to standard monoclonal antibodies. For example, in June 2025, Merck & Co. Inc., a U.S.-based biopharmaceutical company, received FDA approval for ENFLONSIA (clesrovimab-cfor), a long-acting monoclonal antibody designed to prevent RSV lower-respiratory-tract disease in infants during or entering their first RSV season. This fully human IgG1κ antibody includes Fc-region modifications to extend its half-life and binds to the RSV fusion (F) protein, preventing viral entry into host respiratory epithelial cells. It is intended to provide long-lasting protection with a single dose, offering a novel immunization option for this vulnerable pediatric population.
Major companies operating in the respiratory syncytial virus (rsv) fusion inhibitors market are Merck & Co. Inc., Pfizer Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Sanofi S.A., Gilead Sciences Inc., Johnson & Johnson, Taisho Pharmaceutical Co. Ltd., Enanta Pharmaceuticals Inc., Shanghai Ark Biopharmaceutical Co. Ltd., Medivir AB, ARNAV Biotech
North America was the largest region in the respiratory syncytial virus (RSV) fusion inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Respiratory Syncytial Virus (RSV) Fusion Inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The respiratory syncytial virus (RSV) fusion inhibitors market consists of sales of inhalation or nasal spray formulations, long-acting biologics or peptides under development, and combination therapies with other antiviral or supportive agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Respiratory Syncytial Virus (RSV) Fusion Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on respiratory syncytial virus (rsv) fusion inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for respiratory syncytial virus (rsv) fusion inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory syncytial virus (rsv) fusion inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Small Molecule Inhibitors; Monoclonal Antibodies; Peptide Inhibitors; Other Drugs
2) By Route Of Administration: Oral; Intravenous; Inhalation; Other Routes Of Administration
3) By Application: By Prophylaxis; Treatment
4) By End-User: Hospitals; Clinics; Research Institutes; Other End Users
Subsegments:
1) By Small Molecule Inhibitors: Fusion Protein Inhibitors; Viral Entry Blockers; Replication Inhibitors; Nucleoside Analogues
4. Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Inhibitors
Monoclonal Antibodies
Peptide Inhibitors
Other Drugs
6.2. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Inhalation
Other Routes Of Administration
6.3. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
By Prophylaxis
Treatment
6.4. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Research Institutes
Other End Users
6.5. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fusion Protein Inhibitors
Viral Entry Blockers
Replication Inhibitors
Nucleoside Analogues
6.6. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neutralizing Antibodies
Prophylactic Antibodies
Therapeutic Antibodies
Combination Antibodies
6.7. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Sub-Segmentation Of Peptide Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fusion Inhibitory Peptides
Receptor Binding Peptides
Entry Blocking Peptides
Synthetic Peptides
6.8. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ribonucleic Acid (RNA) Interference Agents
Host Targeted Inhibitors
Immunomodulators
Small Interfering Agents
7. Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Regional And Country Analysis
7.1. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
9.1. China Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
9.2. China Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
10.1. India Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
11.1. Japan Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
11.2. Japan Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
12.1. Australia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
13.1. Indonesia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
14.1. South Korea Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
14.2. South Korea Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
15.1. Western Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
15.2. Western Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
16.1. UK Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.2. Eastern Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
22.1. Russia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
23.1. North America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
23.2. North America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
24.1. USA Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
24.2. USA Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
26.1. South America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market Overview
26.2. South America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
27.1. Brazil Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Respiratory Syncytial Virus (RSV) Fusion Inhibitors Market
